# Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement

> **NIH NIH R41** · DEEP CREEK PHARMA, LLC · 2022 · $104,488

## Abstract

Project Summary for Supplement to CA254834
This minority administrative supplement to CA254834 requests funds for training Charles Chidi Okechukwu in
the translational objectives of the Phase 1 STTR project and developing new business development and
entrepreneurial skills fir the candidate that will support company growth. The funded Phase 1 STTR project
(CA254834) focuses on demonstrating that a novel FP polymer, CF10, displays improved activity in pre-clinical
models of metastatic colorectal cancer (mCRC). Currently funded Aims are: i) Demonstrate CF10 inhibits CRC
metastatic progression in an orthotopic colon tumor model; ad ii) Demonstrate improved anti-metastatic activity
for CF10 in a rat syngeneic CRC liver met model. With supplement funding, Charles will investigate if CF10 will
be effective in treating CRC with acquired resistance to 5-FU and will be potentiated in combination with
leucovorin (LV; folinic acid), which complements ongoing studies. The supplemental Aims are: S1) Demonstrate
improved anti-metastatic activity for CF10 in 5-FU-resistant orthotopic CRC models; and S2) Evaluate
Leucovorin potentiation of CF10 in 5-FU-resistant orthotopic CRC models. The mentoring plan for Charles will
include training in technical skills related to pre-clinical drug development, translational research, and
entrepreneurship. Training will include interfacing with researchers, clinical experts, and with business
development experts. Charles will also receive mentoring in writing skills, including business plan development,
and presentation skills, including presentation to investors. Training will enhance the long-term career
opportunities of the applicant, including development of a professional network, and advance the goals of the
company in commercializing CF10 technology.

## Key facts

- **NIH application ID:** 10543218
- **Project number:** 3R41CA254834-01A1S1
- **Recipient organization:** DEEP CREEK PHARMA, LLC
- **Principal Investigator:** William H. Gmeiner
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $104,488
- **Award type:** 3
- **Project period:** 2022-02-01 → 2022-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10543218

## Citation

> US National Institutes of Health, RePORTER application 10543218, Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement (3R41CA254834-01A1S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10543218. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*